Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial
| Class:Id | LiteratureReference:9728233 |
|---|
| _displayName | LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial |
|---|
| _timestamp | 2021-04-20 13:05:41 |
|---|
| author | [Person:9728203] Zambrowicz, B
[Person:9728179] Freiman, J
[Person:9728174] Brown, P M
[Person:9728189] Frazier, K S
[Person:9728193] Turnage, A
[Person:9728205] Bronner, J
[Person:9615776] Ruff, D
[Person:9728213] Shadoan, M
[Person:9728144] Banks, P
[Person:9728223] Mseeh, F
[Person:9728200] Rawlins, D B
[Person:9728202] Goodwin, N C
[Person:9728126] Mabon, R
[Person:9728132] Harrison, B A
[Person:2672403] Wilson, A
[Person:9728218] Sands, A
[Person:9623181] Powell, D R |
|---|
| created | [InstanceEdit:9728224] Jassal, Bijay, 2021-04-20 |
|---|
| journal | Clin. Pharmacol. Ther. |
|---|
| pages | 158-69 |
|---|
| pubMedIdentifier | 22739142 |
|---|
| title | LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial |
|---|
| volume | 92 |
|---|
| year | 2012 |
|---|
| (literatureReference) | [Summation:9728530] The human gene SLC5A2 encodes sodium/glucose cotransporter 2...
[ChemicalDrug:9728173] sotagliflozin [extracellular region] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial (9728233)
